PF-3845

• CAT Number: I000714
• CAS Number: 1196109-52-0
• Molecular Formula: C24H23F3N4O2
• Molecular Weight: 456.5
• Purity: ≥95%
• Target: FAAH
• Solubility: DMSO ≥90mg/mL Water <1.2mg/mL Ethanol ≥90mg/mL
• Storage: 3 years -20℃ powder
• IC50: 0.23 uM
• IUPAC Name: N-pyridin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide
• InChI: InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32)
• InChIKey: NBOJHRYUGLRASX-UHFFFAOYSA-N
• SMILES: C1CN(CCC1CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4

PF-3845 (Cat.No:I000714) is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for the degradation of endocannabinoids. By inhibiting FAAH, PF-3845 increases endocannabinoid levels, leading to potential therapeutic effects in pain management, inflammation, and neurological disorders. It is actively studied for its therapeutic potential in preclinical and clinical settings.

Reference

1:The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Tchantchou F, Tucker LB, Fu AH, Bluett RJ, McCabe JT, Patel S, Zhang Y.Neuropharmacology. 2014 Oct;85:427-39. doi: 10.1016/j.neuropharm.2014.06.006. Epub 2014 Jun 14. PMID: 24937045 Free PMC Article2:The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, Boger DL, Cravatt BF, Lichtman AH.Br J Pharmacol. 2012 Apr;165(8):2485-96. doi: 10.1111/j.1476-5381.2011.01445.x. PMID: 21506952 Free PMC Article